Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) EBITDA (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed EBITDA for 7 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 8.49% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.6 million through Dec 2025, up 29.84% year-over-year, with the annual reading at -$22.4 million for FY2025, 0.76% up from the prior year.
  • EBITDA for Q4 2025 was -$6.4 million at Strata Critical Medical, down from -$5.6 million in the prior quarter.
  • The five-year high for EBITDA was -$4.2 million in Q1 2021, with the low at -$35.6 million in Q4 2023.
  • Average EBITDA over 5 years is -$10.7 million, with a median of -$9.7 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 5954.59% in 2021, then soared 83.43% in 2024.
  • Over 5 years, EBITDA stood at -$10.5 million in 2021, then plummeted by 86.77% to -$19.7 million in 2022, then crashed by 81.08% to -$35.6 million in 2023, then skyrocketed by 83.43% to -$5.9 million in 2024, then decreased by 8.49% to -$6.4 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$6.4 million, -$5.6 million, and -$5.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.